Androphy EJ, Dvoretzky I, Lowy DR. X-linked inheritance of epidermodysplasia verruciformis. Genetic and virologic studies of a kindred. Arch Dermatol. 1985 Jul. 121(7):864-8. [QxMD MEDLINE Link].
Gober MD, Rady PL, He Q, Tucker SB, Tyring SK, Gaspari AA. Novel homozygous frameshift mutation of EVER1 gene in an epidermodysplasia verruciformis patient. J Invest Dermatol. 2007 Apr. 127(4):817-20. [QxMD MEDLINE Link].
Patel T, Morrison LK, Rady P, Tyring S. Epidermodysplasia verruciformis and susceptibility to HPV. Dis Markers. 2010. 29(3-4):199-206. [QxMD MEDLINE Link].
Toyoda H, Ido M, Nakanishi K, Nakano T, Kamiya H, Matsumine A, et al. Multiple cutaneous squamous cell carcinomas in a patient with interferon gamma receptor 2 (IFN gamma R2) deficiency. J Med Genet. 2010 Sep. 47(9):631-4. [QxMD MEDLINE Link].
Yoshida R, Kato T, Kawase M, Honda M, Mitsuishi T. Two sisters reveal autosomal recessive inheritance of epidermodysplasia verruciformis: a case report. BMC Dermatol. 2014 Jul 21. 14(1):12. [QxMD MEDLINE Link]. [Full Text].
Przybyszewska J, Zlotogorski A, Ramot Y. Re-evaluation of epidermodysplasia verruciformis: Reconciling more than 90 years of debate. J Am Acad Dermatol. 2017 Jun. 76 (6):1161-1175. [QxMD MEDLINE Link].
Sun XK, Chen JF, Xu AE. A homozygous nonsense mutation in the EVER2 gene leads to epidermodysplasia verruciformis. Clin Exp Dermatol. 2005 Sep. 30(5):573-4. [QxMD MEDLINE Link].
Lazarczyk M, Pons C, Mendoza JA, Cassonnet P, Jacob Y, Favre M. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J Exp Med. 2008 Jan 21. 205(1):35-42. [QxMD MEDLINE Link].
Kalińska-Bienias A, Kowalewski C, Majewski S. The EVER genes - the genetic etiology of carcinogenesis in epidermodysplasia verruciformis and a possible role in non-epidermodysplasia verruciformis patients. Postepy Dermatol Alergol. 2016 Apr. 33 (2):75-80. [QxMD MEDLINE Link].
Ogawa Y, Kinoshita M, Shimada S, Kawamura T. Zinc and Skin Disorders. Nutrients. 2018 Feb 11. 10 (2):[QxMD MEDLINE Link].
McDermott DF, Gammon B, Snijders PJ, et al. Autosomal dominant epidermodysplasia verruciformis lacking a known EVER1 or EVER2 mutation. Pediatr Dermatol. 2009 May-Jun. 26(3):306-10. [QxMD MEDLINE Link].
Crequer A, Troeger A, Patin E, Ma CS, Picard C, Pedergnana V, et al. Human RHOH deficiency causes T cell defects and susceptibility to EV-HPV infections. J Clin Invest. 2012 Sep. 122 (9):3239-47. [QxMD MEDLINE Link].
Crequer A, Picard C, Patin E, D'Amico A, Abhyankar A, Munzer M, et al. Inherited MST1 deficiency underlies susceptibility to EV-HPV infections. PLoS One. 2012. 7 (8):e44010. [QxMD MEDLINE Link].
Li SL, Duo LN, Wang HJ, Dai W, Zhou EH, Xu YN, et al. Identification of the LCK mutation in an atypical epidermodysplasia verruciformis family with T cell defects and virus-induced squamous cell carcinoma. Br J Dermatol. 2016 Apr 18. [QxMD MEDLINE Link].
de Jong SJ, Imahorn E, Itin P, Uitto J, Orth G, Jouanguy E, et al. Epidermodysplasia Verruciformis: Inborn Errors of Immunity to Human Beta-Papillomaviruses. Front Microbiol. 2018. 9:1222. [QxMD MEDLINE Link].
Liu YQ, Zhang GL, Mo XH, Wang B, Wu F, Chen J, et al. A novel homozygous DOCK8 mutation associated with unusual coexistence of gross molluscum contagiosum and epidermodysplasia verruciformis in a DOCK8 deficiency patient. J Eur Acad Dermatol Venereol. 2017 Nov. 31 (11):e504-e505. [QxMD MEDLINE Link].
Tahiat A, Badran YR, Chou J, Cangemi B, Lefranc G, Labgaa ZM, et al. Epidermodysplasia verruciformis as a manifestation of ARTEMIS deficiency in a young adult. J Allergy Clin Immunol. 2017 Jan. 139 (1):372-375.e4. [QxMD MEDLINE Link].
Uddin KMF, Amin R, Majumder SN, Aleem MA, Rahaman A, Dity NJ, et al. An ANKRD26 nonsense somatic mutation in a female with epidermodysplasia verruciformis (Tree Man Syndrome). Clin Case Rep. 2018 Aug. 6 (8):1426-1430. [QxMD MEDLINE Link].
Vahidnezhad H, Youssefian L, Saeidian AH, Mansoori B, Jazayeri A, Azizpour A, et al. A CIB1 Splice-Site Founder Mutation in Families with Typical Epidermodysplasia Verruciformis. J Invest Dermatol. 2018 Nov 29. [QxMD MEDLINE Link].
Youssefian L, Vahidnezhad H, Mahmoudi H, Saeidian AH, Daneshpazhooh M, Kamyab Hesari K, et al. Epidermodysplasia Verruciformis: Genetic Heterogeneity and EVER1 and EVER2 Mutations Revealed by Genome-Wide Analysis. J Invest Dermatol. 2019 Jan. 139 (1):241-244. [QxMD MEDLINE Link].
Notarangelo LD. HPV: CIB1 is for EVER and EVER. J Exp Med. 2018 Sep 3. 215 (9):2229-2231. [QxMD MEDLINE Link].
de Jong SJ, Créquer A, Matos I, et al. The human CIB1-EVER1-EVER2 complex governs keratinocyte-intrinsic immunity to β-papillomaviruses. J Exp Med. 2018 Sep 3. 215 (9):2289-2310. [QxMD MEDLINE Link].
Jacobelli S, Laude H, Carlotti A, Rozenberg F, Deleuze J, Morini JP, et al. Epidermodysplasia verruciformis in human immunodeficiency virus-infected patients: a marker of human papillomavirus-related disorders not affected by antiretroviral therapy. Arch Dermatol. 2011 May. 147(5):590-6. [QxMD MEDLINE Link].
Imahorn E, Yüksel Z, Spoerri I, Gürel G, Imhof C, Saraçoğlu ZN, et al. Novel TMC8 splice site mutation in epidermodysplasia verruciformis and review of HPV infections in patients with the disease. J Eur Acad Dermatol Venereol. 2017 Oct. 31 (10):1722-1726. [QxMD MEDLINE Link].
Ovits CG, Amin BD, Halverstam C. Acquired Epidermodysplasia Verruciformis and Its Relationship to Immunosuppressive Therapy: Report of a Case and Review of the Literature. J Drugs Dermatol. 2017 Jul 1. 16 (7):701-704. [QxMD MEDLINE Link].
Schultz B, Nguyen CV, Jacobson-Dunlop E. Acquired epidermodysplasia verruciformis in setting of tumor necrosis factor-α inhibitor therapy. JAAD Case Rep. 2018 Sep. 4 (8):805-807. [QxMD MEDLINE Link].
Zavattaro E, Azzimonti B, Mondini M, et al. Identification of defective Fas function and variation of the perforin gene in an epidermodysplasia verruciformis patient lacking EVER1 and EVER2 mutations. J Invest Dermatol. 2008 Mar. 128(3):732-5. [QxMD MEDLINE Link].
Azzimonti B, Mondini M, De Andrea M, et al. CD8+ T-cell lymphocytopenia and lack of EVER mutations in a patient with clinically and virologically typical epidermodysplasia verruciformis. Arch Dermatol. 2005 Oct. 141(10):1323-5. [QxMD MEDLINE Link].
de Oliveira WR, Rady PL, Grady J, et al. Polymorphisms of the interleukin 10 gene promoter in patients from Brazil with epidermodysplasia verruciformis. J Am Acad Dermatol. 2003 Oct. 49(4):639-43. [QxMD MEDLINE Link].
Kao G, et al. Cutaneous carcinogenesis: Etiologic Factors-Viruses. Miller S, Mahoney M, eds. Cutaneous Oncology: Pathophysiology, Diagnosis, and Treatment. London, England: Blackwell Science; 1997. 148-157.
Smola S. Immunopathogenesis of HPV-Associated Cancers and Prospects for Immunotherapy. Viruses. 2017 Sep 12. 9 (9):[QxMD MEDLINE Link].
Marthaler AM, Podgorska M, Feld P, Fingerle A, Knerr-Rupp K, Grässer F, et al. Identification of C/EBPα as a novel target of the HPV8 E6 protein regulating miR-203 in human keratinocytes. PLoS Pathog. 2017 Jun. 13 (6):e1006406. [QxMD MEDLINE Link].
Podgórska M, Ołdak M, Marthaler A, Fingerle A, Walch-Rückheim B, Lohse S, et al. Chronic Inflammatory Microenvironment in Epidermodysplasia Verruciformis Skin Lesions: Role of the Synergism Between HPV8 E2 and C/EBPβ to Induce Pro-Inflammatory S100A8/A9 Proteins. Front Microbiol. 2018. 9:392. [QxMD MEDLINE Link].
Vu J, Wallace GR, Singh R, et al. Common variable immunodeficiency syndrome associated with epidermodysplasia verruciformis. Am J Clin Dermatol. 2007. 8(5):307-10. [QxMD MEDLINE Link].
Morrison C, Eliezri Y, Magro C, Nuovo GJ. The histologic spectrum of epidermodysplasia verruciformis in transplant and AIDS patients. J Cutan Pathol. 2002 Sep. 29(8):480-9. [QxMD MEDLINE Link].
Berthelot C, Dickerson MC, Rady P, et al. Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. J Am Acad Dermatol. 2007 May. 56(5):882-6. [QxMD MEDLINE Link].
Kunishige JH, Hymes SR, Madkan V, et al. Epidermodysplasia verruciformis in the setting of graft-versus-host disease. J Am Acad Dermatol. 2007 Nov. 57(5 Suppl):S78-80. [QxMD MEDLINE Link].
Henley JK, Hossler EW. Acquired epidermodysplasia verruciformis occurring in a renal transplant recipient. Cutis. 2017 May. 99 (5):E9-E12. [QxMD MEDLINE Link].
Majewski S, Skopinska M, Bollag W, Jablonska S. Combination of isotretinoin and calcitriol for precancerous and cancerous skin lesions. Lancet. 1994 Nov 26. 344(8935):1510-1. [QxMD MEDLINE Link].
Myers DJ, Fillman EP. Epidermodysplasia Verruciformis. StatPearls. 2018 Jan. [QxMD MEDLINE Link]. [Full Text].
Partridge ME, Pariser RJ. Ocular and cutaneous squamous cell carcinoma in an African American man with epidermodysplasia verruciformis resulting in blindness and death. J Am Acad Dermatol. 2003 Nov. 49(5 Suppl):S262-4. [QxMD MEDLINE Link].
Shruti S, Siraj F, Singh A, Ramesh V. Epidermodysplasia verruciformis: three case reports and a brief review. Acta Dermatovenerol Alp Pannonica Adriat. 2017 Sep. 26 (3):59-61. [QxMD MEDLINE Link].
Charny JW, Rady PL, Tyring SK, Kovarik CL. Malignant degeneration of diffuse intertriginous flat warts in a patient with AIDS. JAAD Case Rep. 2018 Jul. 4 (6):562-564. [QxMD MEDLINE Link].
Mitsuishi T, Kawana S, Kato T, Kawashima M. Human papillomavirus infection in actinic keratosis and bowen's disease: comparative study with expression of cell-cycle regulatory proteins p21(Waf1/Cip1), p53, PCNA, Ki-67, and Bcl-2 in positive and negative lesions. Hum Pathol. 2003 Sep. 34(9):886-92. [QxMD MEDLINE Link].
Stetsenko GY, McFarlane RJ, Chien AJ, et al. Subungual Bowen disease in a patient with epidermodysplasia verruciformis presenting clinically as longitudinal melanonychia. Am J Dermatopathol. 2008 Dec. 30(6):582-5. [QxMD MEDLINE Link].
de Koning M, Struijk L, Feltkamp M, ter Schegget J. HPV DNA detection and typing in inapparent cutaneous infections and premalignant lesions. Methods Mol Med. 2005. 119:115-27. [QxMD MEDLINE Link].
Nuovo GJ, Ishag M. The histologic spectrum of epidermodysplasia verruciformis. Am J Surg Pathol. 2000 Oct. 24(10):1400-6. [QxMD MEDLINE Link].
Anadolu R, Oskay T, Erdem C, Boyvat A, Terzi E, Gurgey E. Treatment of epidermodysplasia verruciformis with a combination of acitretin and interferon alfa-2a. J Am Acad Dermatol. 2001 Aug. 45(2):296-9. [QxMD MEDLINE Link].
Gubinelli E, Posteraro P, Cocuroccia B, Girolomoni G. Epidermodysplasia verruciformis with multiple mucosal carcinomas treated with pegylated interferon alfa and acitretin. J Dermatolog Treat. 2003 Sep. 14(3):184-8. [QxMD MEDLINE Link].
Kim C, Hashemi P, Caglia M, Shulman K. Treatment of Imiquimod Resistant Epidermodysplasia Verruciformis With Ingenol Mebutate. J Drugs Dermatol. 2016 Mar. 15 (3):350-2. [QxMD MEDLINE Link].
Majewski S, Jablonska S. Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Arch Dermatol. 1995 Nov. 131(11):1312-8. [QxMD MEDLINE Link].
Hoffner MV, Camacho FM. Surgical treatment of epidermodysplasia verruciformis. Dermatol Surg. 2010 Mar. 36(3):363-7. [QxMD MEDLINE Link].